FDA
Savara shares dropped 18% on the news, though analysts remain confident in approval, instead pointing to potential “bandwidth issues” at the FDA.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.
Actinogen Medical’s lead program for its sole pipeline candidate has failed a late-stage study, but the Australian biotech still plans on taking the findings to the FDA for a path forward.
The go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
FEATURED STORIES
IPO
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant.
The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.
Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
Women held 29% of biotech board seats in fiscal year 2025 but just 8.8% of CEO roles, highlighting uneven progress across industry leadership spots.
How India and other emerging hubs for drug development can be key to reshaping medical costs globally.
FROM BIOSPACE INSIGHTS
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
UPCOMING EVENTS
LATEST PODCASTS
In this episode of Denatured, you’ll hear from Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take to turn existing molecules into viable new therapies.
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
In this episode of Denatured, you’ll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
Subscribe to GenePool
Subscribe to BioSpace’s flagship publication including top headlines, special editions and life sciences’ most important breaking news
SPECIAL EDITIONS
BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
During Q3, there was a 31% year-over-year increase in job postings live on BioSpace. The number of employees affected by layoffs dropped 90%.
As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
DEALS
  1. There’s a party going on at DISCO Pharma’s European headquarters after the precision medicine biotech signed its second major pharma partnership of the year—first Amgen, now AbbVie.
  2. Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
  3. The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
  4. A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
  5. Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
WEIGHT LOSS
  1. The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
  2. As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.
  3. Across three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw said following the company’s ObesityWeek update.
  4. ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persistence on treatment.
  5. With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
POLICY
  1. Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
  2. FDA
    Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.
  3. As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say more predictable funding and regulation could help the U.S. maintain its edge.
  4. Inspection access is not “an administrative footnote,” leaders of key FDA divisions wrote in an editorial on Wednesday vowing to expand oversight of foreign clinical trial sites.
  5. CSL Vifor holds the marketing authorization for Tavneos in the U.K., where the drug is marketed as Avacopan Vifor. It continues to be sold on the U.S. market by Amgen despite concerns raised by the FDA.
CAREER HUB
Your previous employer may have set a high standard. Executive coach Angela Justice explains how holding every company to it can distort your judgment and undermine your influence.
Average jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.
Kaye/Bassman’s Michael Pietrack explores the guilt and grief executives feel when their direct reports are downsized and provides a strategy that helps both the leader and the people who need new jobs.
Compensation can feel like a verdict on your value. Executive coach Angela Justice explains why companies are usually pricing the job, not the person doing it—and how understanding the difference can help you make better career decisions.
Based on typical fourth quarter hiring activity, biopharma job seekers should apply for open roles sooner than later. Recruiting and career coaching experts offer advice on timing, networking, interviewing and casting a wider net than usual during Q4.
A career setback can teach you something useful—or teach you the wrong lesson. Executive coach Angela Justice explains how one difficult experience can quietly shape the choices that follow.
With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the qualifications, technical skills and mindset needed to land these coveted positions.
HOTBEDS
Where are the Best Places to Work in life sciences? BioSpace’s annual Best Places to Work list demonstrates a company’s desirability in the recruitment marketplace - find out who made the list this year.
IN CASE YOU MISSED IT
After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever.
REPORTS
The third quarter offered positive signals for job seekers and talent acquisition teams. Explore BioSpace’s Biopharma Job Market Report Q3 2026 to get a closer look at hiring trends, workforce reductions and the evolving employment landscape across the industry.
What drives meaningful employee engagement in today’s life sciences workplace? This BioSpace report explores the factors that shape how employees feel about their organizations and what employers can do to create workplaces where talent wants to stay and thrive.
This guide explores the evolving role of podcasts, webinars, and thought leadership programs in biopharma and provides practical recommendations for public relations agencies, corporate communications teams, and commercial marketers looking to elevate their visibility and influence.
CANCER
  1. Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
  2. Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
  3. Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
  4. FDA
    The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
  5. FDA
    The FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.
NEUROSCIENCE
  1. At the Clinical Trials on Alzheimer’s Disease Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in schizophrenia.
  2. Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approval based on a positive subgroup signal.
  3. Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events.
  4. This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.
  5. Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
CELL AND GENE THERAPY
  1. It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million.
  2. Novartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while others were set aside for strategic reasons or paused over safety concerns.
  3. In this webinar, we will show how delayed isolation and cryopreservation of immune cells from fresh leukopaks can drastically impact their stability and functionality. We will also explore how purified and cryopreserved cell populations such as PBMCs and isolated T cells streamline logistics, reduce variability, and enhance transduction efficiency in CAR-T production.
  4. Less than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to support commercial production.
  5. Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.